Innocan Pharma announces sale of products and expansion into eastern Europe
by CM Staff
As part of the multi-year Distribution Agreement, UAB Medexy has an exclusive right to distribute both of Innocan's SHIR™ and RELIEF&GO™ brands in Lithuania, Latvia & Estonia.
Innocan Pharma ‘s SHIR™ and RELIEF&GO™ products
HERZLIYA and CALGARY — Innocan Pharma Corporation announces the entering into of a wide-scope commercial distribution agreement with UAB Medexy.
As part of the multi-year Distribution Agreement, UAB Medexy has an exclusive right to distribute both of Innocan’s SHIR™ and RELIEF&GO™ brands in Lithuania, Latvia & Estonia, based on an agreed purchase forecast.
UAB Medexy’s first order under the Distribution Agreement is for over 5000 units of SHIR™ and RELIEF&GO™ products.
UAB Medexy has a background as a Eastern European player in the import and distribution of cosmetic products and medical devices.
The CBD skin care market is estimated to reach USD 10,376.4 M by 2028, according to CBD skin care Market | Global Sales Analysis Report – 2028 (futuremarketinsights.com). Innocan Pharma and SHIR™/ RELIEF&GO™ will now be stepping-up to become market leaders in many European countries.
“We are very excited to distribute Innocan Pharma’s products”, Vidmantas Lozys, UAB Medexy CEO, “We firmly believe that SHIR™ Facial Care will be very well received by our customers, and we assume that this will be an exemplary success story for everyone involved.”
Iris Bincovich, CEO of InnoCan stated that “We are humbled to have a leading European market leader such as UAB Medexy as our market-partner in Lithuania, Latvia & Estonia. This new business will complement both Innocan’s exponential growth strategy and UAB Medexy Health and Beauty market strategy.”
